BioRestorative Therapies, Inc. (BRTX)

1,3200 -0,0200 (-1,49%) Ab 02:01PM EDT. Markt geöffnet.

BioRestorative Therapies, Inc.

40 Marcus Drive
Suite 1
Melville, NY 11747
United States
631 760 8100
https://www.biorestorative.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 11

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Lance Alstodt	Chairman of the Board, President & CEO	954,17k	N/A	1971
Mr. Robert Eugene Kristal	Chief Financial Officer	368,12k	N/A	1968
Mr. Francisco J. Silva	Chief Scientist, VP of Research & Development, Secretary and Director	891,67k	N/A	1975
Mr. Robert Paccasassi	Vice President of Quality Assurance & Regulatory Compliance	233,95k	N/A	1969
Dr. Wayne J. Olan M.D.	Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is based in Melville, New York.

Corporate Governance

BioRestorative Therapies, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.